Int. J. Cancer: 120, (2006)
|
|
- Mariah Neal
- 5 years ago
- Views:
Transcription
1 Int. J. Cancer: 120, (2006) ' 2006 Wiley-Liss, Inc. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section Khatami Ali 1 *, Aus Gunnar 1, Damber Jan-Erik 1, Lilja Hans 2,3, Lodding P ar 1 and Hugosson Jonas 1 1 Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden 2 Department of Clinical Laboratories, Urology and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 3 Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital (UMAS), Malm o, Sweden This study reports the outcome of active surveillance in men with PSA screening-detected prostate cancer (PC), and PSA doubling time (PSADT) was evaluated as a predictor of selecting patients to active treatment or surveillance. On December 31, 1994, 10,000 men were randomized to biennial PSA testing. Through to December 2004, a total of 660 men were diagnosed with PC, of whom 270 managed with initial surveillance. Of these 270 patients, 104 (39%) received active treatment during follow-up, 70 radical prostatectomy, 24 radiation and 10 endocrine treatment. Those who received active treatment during follow-up (mean 63 months) were significantly younger (62.6 vs years, p < ) and had a shorter PSADT (3.7 vs. 12 years, p < ). PSA relapse was observed in 9 of 70 patients who received RRP during a mean follow-up of 37 months. Seven of these nine PSA relapses were in the patients with preoperative PSADT < 2 years. None of the 37 operated patients with a PSADT > 4 years had a PSA relapse. In a Cox regression analysis adjusted for PSA, ratio-free PSA and amount of cancer in biopsy, only the preoperative PSADT was statistically significant predictor of PSA relapse in p The optimal candidate for surveillance is a man with early, low-grade, low-stage PC and a PSADT > 4 years. In younger men with a PSADT of less than 4 years, surveillance does not seem to be a justified alternative, and patient should be informed about the risk with such an approach. ' 2006 Wiley-Liss, Inc. Key words: prostate cancer; surveillance; PSA doubling time; radical prostatectomy Surveillance has for a long time been a treatment option in men with prostate cancer (PC). The reason for choosing surveillance and not active treatment is the slow progression rate sign in most men diagnosed with PC. Many men with early stage PC will, in the absence of active treatment, die of causes other than PC. 1 Lately, 1 randomized trial data has emerged about the efficacy of active treatment versus surveillance. In the SPCG 4 study, it was shown that radical prostatectomy was superior to surveillance, but as many as 19 men needed to be treated to save 1 person from dying of PC. 2 In the last report from this study, as many as 86% of the men in surveillance were still alive or died of causes other than PC, after a median follow-up of 8.3 years. Particularly in elderly men and men with a short life expectancy due to comorbidities, surveillance might be an option to avoid or postpone the side effects of treatment. Traditionally, surveillance has been followed by hormonal treatment at the time symptomatic disease occurs. 3 However, in recent years, PC in many men is detected at an earlier stage and a new type of surveillance has been popularized. Klotz has shown that many men with early PC may be put on initial surveillance followed by curative-intended treatment later on. 4 In a population invited to repeated PSA testing, the majority of cancers detected are in the early stage. 5 As the lead-time in PSAdetected cases will add 5 10 years to the natural course of the disease, many men will not develop symptoms for many years. 6 Treating all these cases could probably result in overtreatment. To avoid overtreatment, some authors have recommended initial surveillance. 7 Surveillance could either be followed by curativeintended treatment at PSA progression in younger men or by hormonal manipulation in men with limited life expectancy if symptomatic disease occurs. On the other hand, men who have been taking part in PSA screening have done so in order to avoid the development of advanced PC. This implies that, if surveillance is chosen in these cases, it must be a safe strategy. Scientific data identifying screening-detected PC who are suitable for surveillance is currently lacking. The present study presents the outcome of initial surveillance in 270 men with PC detected by PSA screening, and evaluates the role of the PSA doubling time (PSADT) as a tool for selecting the correct patients for surveillance. Patients and methods Sahlgrenska University Hospital in Gothenburg is the Swedish branch of the European Randomized Study of Prostate Cancer. From a group of 20,000 men born between January 1, 1930, and December 31, 1944, 10,000 were randomized into a screening group, and 10,000 were randomized into a control group. Patients in the screening group were invited to the first PSA testing between 1995 and 1996, and were then invited for PSA testing every second year thereafter. Men with PSA levels 3 ng/ml were offered to undergo clinical investigation, which included sextant biopsy of the prostate. Only minor corrections of the study protocol have been made so far. 5 A total of 660 men were diagnosed with PC as a result of the screening procedure through to December Of these, 270 (41%) men were managed primarily with surveillance. Surveillance was defined as an active standpoint to postpone the treatment until at least 6 months after diagnosis. The reasons for choosing surveillance were comorbidity, smallvolume cancers in biopsies or patient s desire. In many cases, there was more than 1 reason for choosing surveillance. Smallvolume cancers in biopsies were classified as 1 or 2 adjacent cores with a total core cancer length of less than 2 mm and where rebiopsies of the area did not reveal more cancer. 8 Patients managed by surveillance were generally scheduled for follow-up visits every 6 months with PSA and clinical investigation. Patients with no signs of progression after 2 years were generally controlled at an annual basis. Rebiopsies were not mandatory during follow-up. Rebiopsies were normally recommended only in patients who had signs of T-stage progression and/or PSA progression and when the physician (and the patient) were in doubt about whether active treatment should be chosen or not. Only 34 patients were rebiopsied during the follow-up. Bone-scans were generally not carried out in patients with PSA < 20 ng/ml and a Gleason score (GS) of < 8. Grant sponsor: Gothenburg Medical Society; Grant sponsor: Swedish Cancer Society; Grant number: 3792-B96-01XAB, 3555; Grant sponsor: National Cancer Institute; Grant number: P50-CA92629; Grant sponsor: European Union 6th Framework; Grant number: LSHC-CT *Correspondence to: Sahlgrenska University Hospital, Department of Urology, Gothenburg, Sweden. Fax: ali.khatami@urology.gu.se Received 7 March 2006; Accepted after revision 23 May 2006 DOI /ijc Published online 29 September 2006 in Wiley InterScience ( wiley.com). Publication of the International Union Against Cancer
2 OUTCOME AFTER SURVEILLANCE IN PROSTATE CANCER 171 TABLE I DISTRIBUTION OF PSA, RATIO-FREE PSA, PSA DENSITY (PSAD) AND TNM-STAGE IN DIFFERENT AGE CATEGORIES Number of patients 6 (2) 1 44 (16) 99 (37) 121 (45) 270 (100) PSA (mean/median) 4.7/3.6 [ ] 2 5.0/4.5 [ ] 4.7/3.9 [ ] 5.8/4.3 [ ] 5.2/4.2 [ ] PSAD (mean/median) 0.16/0.14 [ ] 0.16/0.14 [ ] 0.14/0.11 [ ] 0.16/0.13 [ ] 0.15/0.12 [ ] Ratio-free PSA 11.1/8.9 [ ] 16.5/15.7 [ ] 19.3/18.2 [ ] 19.6/18.5 [ ] 18.8/17.8 [ ] (mean/median) T1c (no. of patients) (87) T2 (no. of patients) (12.6) T3 (no. of patients) (0.4) 1 Values in parentheses indicate percentages. 2 Values in square brackets indicate ranges. TABLE II CORE BIOPSY INFORMATION AT DIAGNOSIS IN DIFFERENT AGE CATEGORIES Number of patients with 1 core with cancer 2 (33) 1 25 (57) 71 (71) 87 (72) 185 (69) 2 3 cores with cancer 3 (50) 14 (32) 24 (24) 29 (24) 70 (26) 4 6 cores with cancer 1 (17) 5 (11) 4 (4) 5 (4) 15 (5) cancer length in core 9.0/6.2 [ ] 2 4.6/2.5 [ ] 3.2/1.7 [ ] 3.0/1.7 [ ] 3.4/1.9 [ ] biopsy, mean/median (mm) Number of patients with Gleason score (2.5) 0 2 (1.6) 3 (1) Gleason score (2.5) 3 (3) 3 (2.5) 7 (3) Gleason score (100) 42 (95) 96 (97) 107 (88.5) 251 (93) Gleason score (7.4) 9 (3) 1 Values in parentheses indicate percentages. 2 Values in square brackets indicate ranges. The patient s age, PSA, free/total PSA and PSA density at diagnosis were registered. The core biopsy information, including the total number of cores, number of cores with cancer, total length of cancer in the biopsy, the GS and the clinical tumor stage according to TNM classification (1992), were prospectively registered into the database. During follow-up, new information, including the PSA at the time of active treatment and the type of treatment following surveillance, were registered. Switching to active treatment was recommended in patients with established PSA, stage or grade progression. However, in many men with stable PSA and no other signs of progression, switching to active treatment was initiated by patient s desire. The characteristics of the entire surveillance group at diagnosis, stratified according to age group, are presented in Table I. The median age was 64.6 ( ) years; the median PSA at diagnosis was 4.2 ( ) ng/ml. Of the patients, 87% had T1c and none of the patients were N1 or M1. Table II presents the diagnostic sextant core biopsy information: 97% of patients had Gleason or less, all the patients with a GS of more than were in the age group years. Of the patients, 69% had cancer in 1 core, and only 5% had cancer in more than 3 cores. The median of the total cancer length in biopsies was 1.9 ( ) mm. PSA doubling time (PSADT) was calculated based on PSA measurements at least 3 months apart. PSADT was estimated for each patient as the reciprocal of the slope from regression of log-2 PSA on time. 9 We used the PSA at diagnosis and the latest PSA value before any active treatment was received or at last follow-up for the patients still in surveillance. In patients having radical prostatectomy, the technique was as previously described. 10 No neoadjuvant endocrine treatment was given. PSA relapse in the radical retropubic prostatectomy (RRP) group was defined as 2 consecutive PSA elevations above 0.2 ng/ml. Radiation therapy was given as external beam radiation in 8 patients with 70 Gy. Fourteen patients were treated using combination therapy with high dose rate Iridium implants combined with external radiation. Two patients were treated with seed implants. The majority of radiated patients received hormonal therapy for 6 months, starting 3 months before radiation. PSA relapse in radiated patients was defined according to the ASTRO criteria. The 2 endpoint of the study were to evaluate if PSADT could predict the patients who would switch to active treatment during the follow-up and the power of PSADT as a predictor of PSA relapse after RRP. Differences in continuous prognostic markers (PSA, ratio-free to total PSA, PSA-density, PSADT, total cancer length in biopsies and age) between groups were tested by the Mann Whitney method. The Kaplan Meier estimates were used for calculating time to active treatment (patients were considered censored at time of last follow-up or death due to other causes) and to calculate PSA-free survival in men treated with RRP. The influence of possible preoperative prognostic covariates on PSA-free survival after RRP was tested in a Cox regression model. A p-value of < 0.05 was regarded as significant. All analysis was performed using the SAS statistical program. Results The mean follow-up time was 63 (11 120) months. During this time period, 104 (39%) patients changed from surveillance to active treatment with RRP in 70 (67%) patients, radiation therapy in 24 (23%) patients and hormonal therapy in 10 (10%) patients. During the follow-up, another 10 patients had been treated due to urinary obstructive symptoms; 3 with TURP, 1 with TUMT and 6 with 5a-reductase inhibitors. Of the patients in the age group at diagnosis, only 16.7% continued surveillance compared with 77.7% in the age group (Table III). The distribution of different prognostic markers in those who received active treatment and those who were still under surveillance is presented in Table IV. Patients who received active treatment were significantly younger (p < ), had a lower free PSA ratio (p ) and a higher amount of cancer in the biopsies (p ). The median PSADT in patients still under surveillance was 12.0 years compared with 3.7 years (p < ) in those who changed to active treatment. There was no statistical significant difference in PSA at diagnosis or PSA density between
3 172 KHATAMI ET AL. TABLE III THE NUMBER OF PATIENTS WHO RECEIVED SECOND LINE THERAPIES AFTER INITIAL SURVEILLANCE IN DIFFERENT AGE CATEGORIES Radical prostatectomy 4 (66.7) 1 19 (43.2) 35 (35.4) 12 (9.9) 70 (25.9) Radiotherapy 1 (16.7) 5 (11.4) 9 (9.1) 9 (7.4) 24 (8.9) Hormonal treatment 0 1 (2.3) 3 (3) 6 (5.0) 10 (3.7) LUTS treatment (6.8) 2 (2) 5 (4.1) 10 (3.7) Continuing surveillance 1 (16.7) 16 (36.4) 50 (50.5) 89 (73.6) 156 (57.8) 6 (100) 44 (100) 99 (100) 121 (100) 270 (100) 1 Values in parentheses indicate percentages. 2 Symptomatic treatments were TURP in 3 patients, TUMT in 1 patient and 5a-reductase inhibitor in 6 patients. TABLE IV DISTRIBUTION OF PROGNOSTIC MARKERS BETWEEN THE ACTIVE TREATMENT AND SURVEILLANCE GROUPS Continued surveillance Active treatment RRP Radiation Hormonal Active treatment (all) p-value (active treatment vs. surveillance) PSA at diagnosis 5.2 (4.2) (4.1) 4.9 (4.2) 5.0 (3.9) 8.2 (7.0) 5.3 (4.2) 0.41 Ratio-free PSA (%) 18.8 (17.8) 19.9 (19.3) 17.3 (16.7) 17.0 (15.7) 15.5 (13.9) 17 (16) PSA-density 0.15 (0.12) 0.15 (0.12) 0.15 (0.12) 0.16 (0.13) 0.21 (0.17) 0.16 (0.13) 0.52 TCL 2 in biopsy 3.4 (1.9) 2.9 (1.6) 3.2 (2.0) 6.9 (4.6) 6.4 (6.6) 4.3 (2.5) (64.5) 64.8 (65.5) 61.6 (62) 63.0 (64.3) 64.4 (65.5) 62.1 (62.6) < PSA at treatment 6.7 (5.9) 7.7 (5.4) 11.9 (9.9) 7.4 (5.9) Time to treatment 28.4 (21.0) 21.2 (15.4) 36.6 (24.6) PSADT (7.1) (I10.8) (3.8) (2.5) (5.0) (3.7) < Values in parentheses indicate medians. 2 TCL, total cancer length. FIGURE 1 Patients who received active treatments during the follow up, stratifying by PSADT < 2 years (28), PSADT 2 4 years (49) and PSADT > 4 years (188) (no. of patients). Patients at risk: Year , Y , Y , Y6 5 80, Y8 5 51, Y the 2 groups. Figure 1 illustrates the time to active treatment stratified for different PSADT intervals. The mean time from diagnosis to RRP was 28.4 (7.6 95) months. The mean PSA at diagnosis was 4.9 (3 13), and the mean PSA at the time of treatment was 6.7 (3.3 15) in the RRP group. The median PSADT in the RRP group was 3.8 years compared with 7.0 years for the entire surveillance population. The corresponding data for patients who received radiation or hormonal therapy are presented in Table IV. The pathological assessment of RRP specimens resulted in an upgrading of the GS in 15 (21%) patients, from GS 3 1 2to51 3 FIGURE 2 PSA-free survival after radical prostatectomy in different PSADT categories. PSADT < 2 years (14), PSADT 2 4 years (18) and PSADT > 4 years (38) (no. of patients). Patients at risk: Year , Y2 5 40, Y4 5 23, Y6 5 8, Y in 1 case, from GS 3 1 3to41 3in1caseandfromGS31 3to in 13 cases. Downgrading was observed in 9 (13%) patients, from GS 3 1 3to31 2in8casesandto31 1 in 1 case. The pathologic stagewaspt2in60(86%)patientsandpt3in10(14%)cases.two cases had seminal vesicle invasion. The positive margin rate was 23%. During a mean follow-up of 37 months, 9 (13%) of the patients in the RRP group had a PSA relapse. Of the 9 patients who had relapsed, 7 had a preoperative PSADT of less then 2 years and the other 2 had a PSADT between 2 and 4 years. There was not a single PSA relapse in the patients with a preoperative PSADT more than 4 years (Fig. 2). The result of the Cox regression analysis, including PSA at diagnosis, free to total PSA and total length of cancer in biopsy, confirmed that the preoperative PSADT was significantly correlated with PSA relapse after RRP (p , Table V).
4 OUTCOME AFTER SURVEILLANCE IN PROSTATE CANCER 173 TABLE V COX REGRESSION ANALYSIS INCLUDING PSA, RATIO FREE-PSA, TOTAL CANCER LENGTH IN BIOPSY-TCL AND PSADT Variable 1 Parameter estimate 2 Standard deviation Risk ratio p-value PSA Ratio-free PSA TCL 3 in biopsy PSADT Each variable is tested as a predictor for risk of PSA relapse after radical prostatectomy. 2 Parameter estimate is the logarithm of the risk ratio; a negative value illustrates that a long PSADT reduces the risk of PSA relapse. 3 TCL, total cancer length. In patients who received radiation therapy, 1 patient had relapsed. Among the 10 patients who received delayed hormonal treatment, none so far had reached a hormone insensitive stage. During the follow-up, 14 patients in the study population died from reasons other than PC. None of these patients had received active treatment. At the most recent PSA assessment, only 5 patients had a PSA exceeding 20 ng/ml, and all of these patients were still in the surveillance group. In spite of the fact that not all the patients had undergone a bone scan, there was no patient who clinically manifested with bone metastasis or other metastasis during the follow-up. Discussion In this study, we observed wide distribution of PSADT very similar to other reports. 7 A majority of men have a very long PSADT, and the number of men that have a short doubling time is relatively few. The rate of men with a PSADT exceeding 4 years was 67 %. It was obvious that men with a short PSADT were the ones who rapidly switched to active treatment (Fig. 1). Many men who initially chose surveillance will discontinue surveillance, because of PSA progression. In 1 study of men younger than 70 years, 57.3 and 73.2% had discontinued surveillance after 2 and 4 years, respectively. 11 In the present study, 50% were still on surveillance after 7 years (Fig. 1). One reason for this difference could be that the patients in our study were detected in an ambitious screening programme, and many very early cancers were detected. Another explanation could be that treatment traditions differ. In Scandinavia, surveillance has been a common alternative for a long time in men with asymptomatic PC. 12 In this study, apart from PSADT, age at diagnosis influenced the decision to continue surveillance. The majority of younger men discontinued surveillance, while almost 75% of men in the age group years at diagnosis were still under surveillance at last follow-up (Table III). As younger men in general have a long life expectancy and according to this and other studies they discontinue surveillance early, it seems questionable to offer these men surveillance. Although follow-up in this study was up to 10 years, the long-term results with surveillance are still obscure. As these men were detected by PSA-screening, a lead-time on an average of 10 years will be added before clinical symptoms are to be expected. The risk with progression after 10 years is therefore difficult to judge and, as long as such data are missing, it seems questionable to put men with very long life expectancy on longterm surveillance. Conversely, postponing the side-effects of active treatment and the complexity in assessment of different curative treatment options are the two major motives that younger men declare as a reason for choosing the initial surveillance. This period of the initial surveillance is resulting in huge anxiety in these patients. They want to know if this period of surveillance can reduce their chance of cure later on. The lack of reliable prognostic markers is the reason that a limited PSA raise usually leads to change to the active treatment in these patients. For these younger men, it is important to recognize the possible risks associated with such a strategy, if there are subgroups of men in which surveillance is truly associated with increased risk. A few studies have focused on this and have not reported any major increased risk for these patients who have delayed curative treatment. 13 In a previous study, we could conclude that, in selected patients, an average surveillance of 2 years did not reduce the chance of cure by radical prostatectomy. 14 One problem in selecting patients for active surveillance is the lack of reliable prognostic factors in early PCs. The GS is generally assumed to be the best prognostic factor, but the problem is that, in a screening situation, more than 70% of detected cancers are Gleason It is also well known that the Gleason grading based on core biopsies is unreliable. 16 In the present study, 21% of the patients who were later operated were upgraded and 13% were downgraded. To assist these men with early PC in their treatments decision making, the question was raised if the preoperative PSADT could be a prognostic marker of PSA relapse after RRP. The rationale is based on the association between PSA and the volume of PC. 17 The usefulness of PSADT is further demonstrated by the fact that several studies have suggested PSADT to be constant over the time. 9 These data suggest that PSADT could be used as a proxy for growth rate in PC and is measurable even in early PCs. In a study of 200 patients, none of the traditional prognostic factors, grade, stage or PSA at base line was correlated to the PSADT. In the same report, one third of the patients had a PSADT > 10 years. PSADT, therefore, seems to have a potential as a tool in the management of patients who select surveillance. The authors conclude that a PSADT < 2 years can identify the patients at high risk of local progression, in spite of otherwise favorable traditional prognostic factors. 18 The importance of PSA kinetic in prognosis has also been analyzed in men undergoing radical prostatectomy. Preoperative PSA velocity has been identified as a risk factor for progression after RRP 19 and also for later PC-specific mortality. 20 In a recently published paper from Freedland et al., 379 patients with biochemical recurrence after RRP were observed, and the main outcome was PC mortality. The PSADT was the strongest risk factor for PC-specific mortality. 21 In this study, we analyzed the risk of PSA recurrence in those patients who received RRP, as an active treatment following surveillance. Of the patients in our study who received RRP, 9 cases of PSA relapse were observed; 7 of these patients had a preoperative PSADT < 2 years and another 2 cases had a PSADT of < 4 years. There was not a single PSA relapse after RRP in the group of patients with PSADT > 4 years (Fig. 2). The power of PSADT as a prognostic marker of PSA relapse was tested in a Cox regression model adjusted for PSA at diagnosis, free to total PSA and total length of cancer in biopsy (Table V). The PSADT was the only statistically significant predictor of PSA relapse after RRP. Accordingly, men with short PSADT had a high risk of disease progression after radical prostatectomy. This group might have had a better chance of cure if they were treated immediately. One problem is that PSADT is not always established at the time of diagnosis, and thus not available when deciding whether active treatment or surveillance should be chosen. Studies so far have not shown that a limited surveillance in selected patients compromise their chance of cure even if the curative treatment is postponed for up to 2 years. 13,14 The results from the present study question whether this is an appropriate approach in the subgroup of patients with a short PSADT. If PSADT is not available at the time of diagnosis, close surveillance is warranted. Even if it could be questioned whether men with a short PSADT are candidates for surveillance, it is obvious from this study that men with a PSADT longer than 4 years were excellent candidates for this strategy. In the patients with a PSADT > 4 years, who later received radical prostatectomy, no PSA relapses have been observed so far in this study. Overall, the present results from surveillance, with a mean follow-up of 63 months, were very encouraging, with no patients who had developed clinical signs of metastasis, and only 5 of 270 patients who at last follow-up had a PSA exceeding 20 ng/ml.
5 174 KHATAMI ET AL. Conclusion PSADT seems to be a useful, reliable and discriminating prognostic marker of disease progression and active treatment during the follow-up of patients with screening-detected early PC who opt for initial active surveillance. Younger, screen-detected men who opt for an initial period of surveillance with a PSADT > 4 years still have an excellent chance of cure by RRP. However, patients with a short PSADT (<4 years) should be informed about the risk for disease progression. Acknowledgements Our sincere thanks to Mrs. Catrin Bergqvist (statistician/phd). 1. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293: Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352: Van Cangh PJ, Gala JL, Tombal B. Immediate vs. delayed androgen deprivation for prostate cancer. Prostate Suppl 2000;10: Klotz L. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 2004;172(5, Part 2):S48 S50, discussion S50,S Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100: Tornblom M, Eriksson H, Franzen S, Gustafsson O, Lilja H, Norming U, Hugosson J. Lead time associated with screening for prostate cancer. Int J Cancer 2004;108: Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005;47: Dietrick DD, McNeal JE, Stamey TA. Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology 1995;45: Schmid HP, McNeal JE, Stamey TA. Clinical observations on the doubling time of prostate cancer. Eur Urol 1993;23 (Suppl 2): Damber JE, Khatami A. Surgical treatment of localized prostate cancer. Acta Oncol 2005;44: Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostatespecific antigen era. J Clin Oncol 2003;21: References 12. Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience. J Urol 1994;152(5, Part 2): Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002;167: Khatami A, Damber JE, Lodding P, Pihl CG, Hugosson J. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy? A case control study. Scand J Urol Nephrol 2003; 37: Hugosson J, Aus G, Bergdahl S, Fernlund P, Frosing R, Lodding P, Pihl CG, Lilja H. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 2003;92 (Suppl 2): Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol 1998;33: Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989;141: Klotz L. Expectant management with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2002;7: Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003;170: D Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351: Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433 9.
Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationAre Prostate Carcinoma Clinical Stages T1c and T2 Similar?
Clinical Urology Are Clinical Stages T1c and T2 Similar? International Braz J Urol Vol. 32 (2): 165-171, March - April, 2006 Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Athanase Billis,
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationProstate Cancer Innovations in Surgical Strategies Update 2007!
Prostate Cancer Innovations in Surgical Strategies Update 2007! Curtis A. Pettaway, M.D. Professor Department of Urology The University of Texas M. D. Anderson Cancer Center Radical Prostatectomy Pathologic
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationPSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging
european urology 54 (2008) 1073 1080 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer:
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationRadical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Prostatectomy versus Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Ph.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D.,
More informationAnatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy specimens
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Anatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationEUROPEAN UROLOGY 63 (2013)
EUROPEAN UROLOGY 63 (2013) 101 107 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Laurence Klotz on pp. 108 110 of this issue
More informationPROSTATE BIOPSY: IS AGE IMPORTANT FOR DETERMINING THE PATHOLOGICAL FEATURES IN PROSTATE CANCER?
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology AGE AND PATHOLOGY OF PROSTATE CA Vol. 31 (4): 331-337, July - August, 2005 PROSTATE BIOPSY: IS AGE IMPORTANT
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationProposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy
Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1
(2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue
More informationof Nebraska - Lincoln
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Veterans Affairs Staff Publications U.S. Department of Veterans Affairs 8-2000 Detection, Characterization,
More informationUntreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes
Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes A. A. Hussein,* C. J. Welty,* N. Ameli,* J. E. Cowan, M. Leapman,*
More informationPublished Ahead of Print on April 4, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on April 4, 2011 as 10.1200/JCO.2010.32.8112 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.32.8112 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationCumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio
European Urology European Urology 45 (2004) 160 165 Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio Gunnar Aus a,*, Charlotte Becker b, Stefan
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationInsignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction
European Urology European Urology 43 (2003) 455 460 Insignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction Herbert Augustin a,b, Peter G. Hammerer a,c,*,
More informationMultiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy
2384 Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy Matthew R. Cooperberg, MD, MPH 1 Stephen J. Freedland, MD
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationAUA Update Series. Lesson 33 Volume Active Surveillance for Prostate Cancer: Patient Selection and Management
AUA Update Series Lesson 33 Volume 27 2008 Active Surveillance for Prostate Cancer: Patient Selection and Management Learning Objective: At the conclusion of this continuing medical education activity,
More informationPredicting the Probability of Deferred Radical Treatment for Localised Prostate Cancer Managed by Active Surveillance
european urology 54 (2008) 1297 1305 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Predicting the Probability of Deferred Radical Treatment for Localised
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationRadical Prostatectomy or Watchful Waiting in Early Prostate Cancer
The new england journal of medicine original article Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Ph.D., Lars Holmberg, M.D., Ph.D., Hans Garmo, Ph.D., Jennifer
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationRadical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
The new england journal of medicine original article Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D.,
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationBJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent
21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationProstate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:
Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors
More informationA NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY
ADULT UROLOGY CME ARTICLE A NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY MISOP HAN, PETER B. SNOW, JONATHAN I. EPSTEIN, THERESA Y. CHAN,
More informationRadical prostate surgery?
Decipher enables personalized and actionable treatment after surgery Radical prostate surgery? The Decipher Prostate Cancer Classifier can help you and your doctor decide on important next steps in your
More informationInterval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer
DOI 10.1007/s00345-013-1125-0 ORIGINAL ARTICLE Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer D. M. Bolton A. Ta M. Bagnato
More informationTREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME
ADULT UROLOGY TREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME VIBHA BHATNAGAR, SUSAN T. STEWART, WILLIAM W. BONNEY, AND ROBERT M. KAPLAN ABSTRACT
More informationA model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival
British Journal of Cancer (6) 94, 1361 1368 All rights reserved 7 9/6 $3. www.bjcancer.com A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall
More informationRADICAL PROSTATECTOMY IS ONE
ORIGINAL CONTRIBUTION Risk of Prostate Cancer Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy Stephen J. Freedland, MD Elizabeth B. Humphreys, BS Leslie A. Mangold, MS Mario
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationExpanded criteria for active surveillance in prostate cancer: a review of the current data
Review Article Expanded criteria for active surveillance in prostate cancer: a review of the current data Cameron Jones 1, Mina M. Fam 2, Benjamin J. Davies 2 1 University of Pittsburgh School of Medicine,
More informationUse of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer {
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer { (2003) 6, 39 44 ß 2003 Nature Publishing Group All rights reserved 1365 7852/03 $25.00 www.nature.com/pcan
More informationLong-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Published Ahead of Print on December 15, 1 as 1.1/JCO.1.55.119 The latest version is at http://jco.ascopubs.org/cgi/doi/1.1/jco.1.55.119 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term
More informationInterobserver reproducibility of modified Gleason score in radical prostatectomy specimens
Virchows Arch (2004) 445:17 21 DOI 10.1007/s00428-004-1034-0 ORIGINAL ARTICLE Axel Glaessgen Hans Hamberg Carl-Gustaf Pihl Birgitta Sundelin Bo Nilsson Lars Egevad Interobserver reproducibility of modified
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2
Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent
More informationActive Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it fool-proof?
Active Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it fool-proof? Duke Bahn MD Prostate Institute of America, Ventura, California INTRODUCTION In the November
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationORIGINAL INVESTIGATION. Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans. having prostate cancer, assessment
ORIGINAL INVESTIGATION Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans Edward M. Uchio, MD; Mihaela Aslan, PhD; Carolyn K. Wells, MPH; Juan Calderone, MD; John Concato, MD, MS, MPH
More informationAmbulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer
Ambulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer Luigi Benecchi, Anna Maria Pieri, Carmelo Destro Pastizzaro, and Michele Potenzoni OBJECTIVES METHODS RESULTS CONCLUSIONS
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationTo be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for?
To be covered Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? Europa Uomo meeting Stockholm 29 Chris H.Bangma Rotterdam, The Netherlands
More informationPROSTATE-SPECIFIC ANTIGEN (PSA) is a sensitive
Prostate-Specific Antigen Doubling Times Are Similar in Patients With Recurrence After Radical Prostatectomy or Radiotherapy: A Novel Analysis By Bryan D. Leibman, Ozdal Dillioglugil, Peter T. Scardino,
More informationThe Prostate Specific-Antigen (PSA):
The Prostate Specific-Antigen (PSA): Why it could not detect prostate cancer reliably in the past and How it became a sensitive and specific tumor marker Hans H. Glaettli, dipl. Phys. ETH 0. Summary PSA
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationErectile Function Before and After Non-Nerve-Sparing Retropubic Radical Prostatectomy
Archives of Urology ISSN: 2638-5228 Volume 1, Issue 2, 2018, PP: 5-9 Erectile Function Before and After Non-Nerve-Sparing Retropubic Radical Prostatectomy Jørgen Bjerggaard Jensen, MD 1, Jørgen K. Johansen,
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More informationDo all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database
Do all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database Sean Fischer*, Daniel Lin, Ross M. Simon*, Lauren E. Howard, William J. Aronson **,
More informationPretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients
, Vol. 4(1-2), January 2017 Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients Gennady M. Zharinov 1, Oleg A. Bogomolov 1, Natalia N. Neklasova 1, Vladimir
More informationPredictive Factors of Gleason Score Upgrading in Localized and Locally Advanced Prostate Cancer Diagnosed by Prostate Biopsy
www.kjurology.org DOI:10.4111/kju.2010.51.10.677 Urological Oncology Predictive Factors of Gleason Score Upgrading in Localized and Locally Advanced Prostate Cancer Diagnosed by Prostate Biopsy Seung Jin
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationACTIVE SURVEILLANCE FOR PROSTATE CANCER
ACTIVE SURVEILLANCE FOR PROSTATE CANCER Dr. Michael J Metcalfe PGY-2 Department of Urological Sciences April 25, 2012 CASE RM 65 year old active Caucasian male, married. PSA= 7.0 T2a Gleason 3+3=6 2/6
More informationUrological Oncology. Sam Ladjevardi, Anders Berglund*, Eberhard Varenhorst, Ola Bratt, Anders Widmark and Gabriel Sandblom.
Urological Oncology Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20 100 ng/ml Sam Ladjevardi, Anders Berglund*,
More informationEvaluation of pt2 subdivisions in the TNM staging system for prostate cancer
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology HONG et al. BJUI BJU INTERNATIONAL Evaluation of pt2 subdivisions in the TNM staging system for prostate cancer Sung Kyu Hong, Byung Kyu
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationA Competing Risk Analysis of Men Age Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer
A Competing Risk Analysis of Men Age 55-74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer Peter C. Albertsen, MD 1 James A. Hanley, PhD 2 Donald F.Gleason, MD, PhD 3
More informationPSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationMr PHIP No. 1 Prostate cancer: Should I be tested?
Mr PHIP No. 1 cancer: Should I be tested? Having a large prostate doesn t increase your chances of having prostate cancer. No. 1 / 1 Key points cancer is the most common male cancer after skin cancer.
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More information